Please Wait.....
Report
Artificial Intelligence in Drug Discovery Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035
Market Report I 2026-03-05 I 183 Pages I Global Market Insights
The Global Artificial Intelligence In Drug Discovery Market was valued at USD 3.1 billion in 2025 and is estimated to grow at a CAGR of 30.5% to reach USD 43.9 billion by 2035.
The artificial intelligence in the drug discovery industry is witnessing rapid expansion as pharmaceutical and biotechnology companies increasingly integrate advanced computational technologies into research processes. The growing burden of complex and long-term health conditions is encouraging organizations to accelerate the development of innovative therapeutics, which in turn is driving the adoption of AI-driven discovery tools. Artificial intelligence technologies are transforming traditional drug development methods by improving efficiency, reducing research timelines, and optimizing decision-making across the discovery pipeline. These platforms support various research activities by enabling advanced data analysis and predictive modeling across extensive biomedical datasets. Solutions powered by artificial intelligence are widely used to identify biological targets, optimize candidate compounds, design novel molecular structures, and improve early-stage testing processes. Rising concerns regarding the high cost and lengthy duration associated with conventional research and development activities are also encouraging the integration of AI platforms that enhance productivity and accuracy. Furthermore, increasing interest in precision medicine and personalized therapeutic approaches is creating additional demand for intelligent drug discovery solutions capable of analyzing complex biological information. Expanding digital healthcare infrastructure and growing investments in biotechnology innovation across several regions are also contributing to market growth. Continuous research initiatives aimed at developing more transparent and reliable artificial intelligence models are further strengthening the outlook of the global artificial intelligence in drug discovery market.
The software segment accounted for 67.9% share in 2025 and is projected to grow at a CAGR of 30.2% throughout 2026-2035. Software platforms have become a fundamental component of the AI-driven drug discovery ecosystem as organizations increasingly rely on digital solutions to manage vast biomedical datasets and conduct complex predictive analyses. These platforms support critical stages of the drug discovery workflow by enabling researchers to perform computational simulations, molecular modeling, and advanced data interpretation. Continuous advancements in artificial intelligence architectures, including machine learning and deep learning techniques, are enhancing the analytical capabilities of these software tools. The integration of sophisticated algorithms allows researchers to perform large-scale chemical simulations and identify promising therapeutic candidates more efficiently.
The machine learning segment held 82.6% share in 2025. Machine learning technologies have become the primary engine driving innovation in AI-based drug discovery because of their ability to process and interpret highly complex scientific datasets. These algorithms analyze diverse biological and chemical data sources, allowing researchers to generate predictive insights that improve early-stage drug development decisions. Machine learning models enable scientists to identify patterns within genomic information, molecular libraries, and experimental datasets, which significantly accelerates the identification of viable therapeutic candidates. In addition, the growing integration of clinical and real-world data into machine learning models is strengthening the development of personalized treatment strategies. Advancements in cloud computing infrastructure and scalable data processing platforms are further supporting the widespread deployment of machine learning technologies within pharmaceutical research environments.
North America Artificial Intelligence in Drug Discovery Market held 47.7% share in 2025. The North America artificial intelligence in drug discovery industry is experiencing strong growth due to the rapid adoption of advanced digital technologies across pharmaceutical and biotechnology organizations. The region benefits from a highly developed innovation ecosystem that encourages the integration of artificial intelligence solutions into biomedical research activities. Strong financial investment in biotechnology research and digital healthcare infrastructure is further accelerating the development of advanced AI-driven drug discovery platforms. Supportive regulatory frameworks also contribute to market expansion by encouraging the safe and effective use of emerging technologies in healthcare research.
Major companies operating in the Global Artificial Intelligence in Drug Discovery Market include Isomorphic Labs (Alphabet), Microsoft Corporation, NVIDIA Corporation, International Business Machines Corporation, Schrodinger, Recursion Pharmaceuticals, Insilico Medicine, BenevolentAI, Atomwise, Insitro, Deep Genomics, Iktos, Deargen, 9Bio Therapeutics, Aureka Biotechnologies, CellCodex Technology Limited, chAIron, DenovAI Biotech, Examol, Helical.AI, Orakl Oncology, and Therenia. Companies operating in the Global Artificial Intelligence in Drug Discovery Market are implementing multiple strategies to strengthen their technological capabilities and expand market influence. One key approach involves investing heavily in research and development to enhance the performance of AI algorithms used in molecular modeling and predictive analytics. Many organizations are also forming strategic collaborations with pharmaceutical firms, biotechnology companies, and research institutions to accelerate the development of innovative therapeutic solutions. Expanding cloud-based computing infrastructure and high-performance data platforms is another major focus area that allows companies to process large biomedical datasets more efficiently. Additionally, firms are prioritizing the integration of advanced analytics, automation tools, and scalable machine learning models to improve drug discovery workflows.
Report Content
Chapter 1 Methodology and Scope
1.1 Market scope and definition
1.2 Research approach
1.3 Quality commitments
1.3.1 GMI AI policy and data integrity commitment
1.3.1.1 Source consistency protocol
1.4 Research trail and confidence scoring
1.4.1 Research trail components
1.4.2 Scoring components
1.5 Data collection
1.5.1 Partial list of primary sources
1.6 Data mining sources
1.6.1 Paid sources
1.6.1.1 Sources, by region
1.7 Base estimates and calculations
1.7.1 Revenue share analysis
1.7.2 Base year calculation
1.8 Forecast model
1.9 Research transparency addendum
1.9.1 Source attribution framework
1.9.2 Quality assurance metrics
1.9.3 Our commitment to trust
Chapter 2 Executive Summary
2.1 Industry 360 synopsis
2.2 Market Trends
2.2.1 Business trends
2.2.2 Regional trends
2.2.3 Component trends
2.2.4 Technology trends
2.2.5 Application type trends
2.2.6 Therapeutic area trends
2.2.7 End use trends
2.3 CXO perspectives: Strategic imperatives
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of complex and chronic diseases
3.2.1.2 Data explosion and digitization in healthcare
3.2.1.3 Advancements in AI algorithms and computing power
3.2.1.4 Growing collaboration between tech and pharma companies
3.2.2 Industry pitfalls and challenges
3.2.2.1 Data quality and integration issues
3.2.2.2 Regulatory and ethical concerns
3.2.3 Market opportunities
3.2.3.1 Expansion of personalized and precision medicine
3.2.3.2 Emergence of generative AI in molecule design
3.3 Growth potential analysis
3.4 Regulatory landscape (Driven by Primary Research)
3.4.1 North America
3.4.1.1 U.S.
3.4.1.2 Canada
3.4.2 Europe
3.4.3 Asia Pacific
3.4.4 Latin America
3.4.5 Middle East and Africa
3.5 Future market trends (Driven by Primary Research)
3.6 Technological landscape
3.6.1 Current technologies
3.6.2 Emerging technologies
3.7 Investment and funding landscape
3.8 Impact of AI and generative AI on the market
3.9 Porter's analysis
3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2025
4.1 Introduction
4.2 Company market share analysis
4.2.1 North America
4.2.2 Europe
4.2.3 Asia Pacific
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Key developments
4.6.1 Merger and acquisition
4.6.2 Partnership and collaboration
4.6.3 New product launches
4.6.4 Expansion plans
Chapter 5 Market Estimates and Forecast, By Component, 2022 - 2035 ($ Mn)
5.1 Key trends
5.2 Software
5.2.1 On-premise
5.2.2 Cloud-based
5.3 Services
Chapter 6 Market Estimates and Forecast, By Technology, 2022 - 2035 ($ Mn)
6.1 Key trends
6.2 Machine learning
6.2.1 Deep learning
6.2.2 Supervised learning
6.2.3 Unsupervised learning
6.2.4 Other machine learning technologies
6.3 Other technologies
Chapter 7 Market Estimates and Forecast, By Application Type, 2022 - 2035 ($ Mn)
7.1 Key trends
7.2 Molecular library screening
7.3 Target identification
7.4 Drug optimization and repurposing
7.5 De novo drug designing
7.6 Preclinical testing
Chapter 8 Market Estimates and Forecast, By Therapeutic Area, 2022 - 2035 ($ Mn)
8.1 Key trends
8.2 Oncology
8.3 Neurodegenerative diseases
8.4 Inflammatory
8.5 Infectious diseases
8.6 Metabolic diseases
8.7 Rare diseases
8.8 Cardiovascular diseases
8.9 Other therapeutic areas
Chapter 9 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)
9.1 Key trends
9.2 Pharmaceutical and biotechnology companies
9.3 Contract research organizations (CROs)
9.4 Other end users
Chapter 10 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Netherlands
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
Chapter 11 Company Profiles
11.1 Isomorphic Labs (Alphabet)
11.2 Microsoft Corporation
11.3 NVIDIA Corporation
11.4 International Business Machines Corporation
11.5 Schrodinger
11.6 Recursion Pharmaceuticals
11.7 Insilico Medicine
11.8 BenevolentAI
11.9 Atomwise
11.10 Insitro
11.11 Deep Genomics
11.12 Iktos
11.13 Deargen
11.14. 9 Bio Therapeutics
11.15 Aureka Biotechnologies
11.16 CellCodex Technology Limited
11.17 chAIron
11.18 DenovAI Biotech
11.19 Examol
11.20 Helical.AI
11.21 Orakl Oncology
11.22 Therenia
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security